NCR1 and neoplasm: The rate-limiting enzyme involved in tryptophan catabolism, indoleamine 2,3-dioxygenase (IDO), is released by tumor cells and can inhibit the upregulation of NKp46 and NKG2D via blockade of IL-2, again limiting the NK cell’s ability to recognize and kill tumor cells [75].